Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2226 - 2250 of 15149 in total

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated...
Approved
Investigational
Withdrawn
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Asfotase alfa

Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels...
Approved
Investigational
Matched Description: … morbidity and premature death. ... Food and Drug Administration (FDA) on October 23, 2015. ... 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Racephedrine

Approved
Experimental
Matched Categories: … Herbs and Natural Products ... Alpha-and Beta-adrenergic Agonists …

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and ... [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Etrasimod

Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes. Therefore, S1P receptor modulators like etrasimod...
Approved
Matched Iupac: … 3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid …
Matched Description: … 26% remission rate observed in UC 52 and UC 12 trials respectively. ... receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and ... obtained from Pfizer’s Elevate UC Phase III registrational program, consisting of the Elevate UC 52 and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Pegademase

Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Approved
Matched Categories: … Enzymes and Coenzymes ... Antineoplastic and Immunomodulating Agents …

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved
Matched Description: … maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and ... [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Epoetin delta

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Approved
Investigational
Withdrawn
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Pancrelipase protease

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.[A32742, L2543]...
Approved
Matched Description: … cleave peptide bonds and are involved in food digestion. ... Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and ... mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and …
Matched Categories: … Enzymes and Coenzymes …

Pentosan polysulfate

Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties.
Approved
Matched Iupac: … hydroxy-2-{[(3R,4S,5R,6R)-6-hydroxy-4,5-bis(sulfooxy)oxan-3-yl]oxy}-4-(sulfooxy)oxan-3-yl]oxidanesulfonic acid …
Matched Categories: … Genito Urinary System and Sex Hormones …

Technetium Tc-99m sulfur colloid

Technetium 99m sulfur colloid is a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and studies of esophageal transit and gastroesophageal reflux. Following injection or oral administration, single...
Approved
Investigational
Matched Description: … studies of esophageal transit and gastroesophageal reflux. ... detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and ... Depending on site of administration and intended usage, Technetium 99m sulfur colloid enters the capillaries …
Matched Categories: … Indicators and Reagents ... Hepatic and Reticulo Endothelial System ... Technetium (99Mtc), Particles and Colloids …

Elagolix

Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only...
Approved
Investigational
Matched Iupac: … trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoic acid …
Matched Description: … , Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. ... Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis ... and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antigonadotropins and Similar Agents ... elagolix, estradiol and norethisterone …

Terizidone

Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.
Approved
Investigational
Matched Description: … in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and …

Dabigatran

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
Approved
Investigational
Matched Iupac: … carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Mosunetuzumab

Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as...
Approved
Investigational
Matched Description: … [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 ... unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it is an “off-the-shelf ... potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eptifibatide

Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Approved
Investigational
Matched Description: … Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Sulodexide

Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Approved
Investigational
Matched Description: … Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Dienestrol

Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of...
Approved
Investigational
Matched Description: … Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and ... Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness ... include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Ustekinumab

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that...
Approved
Investigational
Matched Description: … and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. ... the interleukin (IL)-12 and IL-23 cytokines. ... IL-23, which are cytokines that are involved in immune and inflammatory responses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Enoxaparin

Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients...
Approved
Matched Description: … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various ... Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Nadroparin

Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once...
Approved
Investigational
Matched Description: … It is derived from porcine sources and has a mean molecular size of 5000 daltons. ... heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and ... The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Parnaparin

Parnaparin is an heparin of low molecular weight with antithrombotic effects.
Approved
Investigational
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Tagraxofusp

Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018...
Approved
Investigational
Matched Description: … fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Donislecel

Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and treatments.[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other...
Approved
Matched Description: … 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and ... other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and ... L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and …
Matched Categories: … Cellular and Gene Therapy …
Displaying drugs 2226 - 2250 of 15149 in total